Display options
Cite
D'Elia RV, Laws TR, Carter A, et al. Targeting the "Rising DAMP" during a Francisella tularensis Infection. Antimicrob Agents Chemother. 2013;57(9):4222-4228doi: 10.1128/AAC.01885-12.
D'Elia, R. V., Laws, T. R., Carter, A., Lukaszewski, R., & Clark, G. C. (2013). Targeting the "Rising DAMP" during a Francisella tularensis Infection. Antimicrobial agents and chemotherapy, 57(9), 4222-4228. https://doi.org/10.1128/AAC.01885-12
D'Elia, Riccardo V, et al. "Targeting the "Rising DAMP" during a Francisella tularensis Infection." Antimicrobial agents and chemotherapy vol. 57,9 (2013): 4222-4228. doi: https://doi.org/10.1128/AAC.01885-12
D'Elia RV, Laws TR, Carter A, Lukaszewski R, Clark GC. Targeting the "Rising DAMP" during a Francisella tularensis Infection. Antimicrob Agents Chemother. 2013 Sep;57(9):4222-4228. doi: 10.1128/AAC.01885-12. Epub 2013 Jun 24. PMID: 23796927; PMCID: PMC3754292.
Copy Download .nbib Format: NLM
Share it on

Antimicrob Agents Chemother. 2013 Sep;57(9):4222-4228. doi: 10.1128/AAC.01885-12. Epub 2013 Jun 24.

Targeting the "Rising DAMP" during a Francisella tularensis Infection.

Antimicrobial agents and chemotherapy

Riccardo V D'Elia, Thomas R Laws, Alun Carter, Roman Lukaszewski, Graeme C Clark

Affiliations

  1. Biomedical Sciences, Dstl Porton Down, Salisbury, United Kingdom [email protected].
  2. Biomedical Sciences, Dstl Porton Down, Salisbury, United Kingdom.

PMID: 23796927 PMCID: PMC3754292 DOI: 10.1128/AAC.01885-12

Abstract

Antibiotic efficacy is greatly enhanced the earlier it is administered following infection with a bacterial pathogen. However, in a clinical setting antibiotic treatment usually commences following the onset of symptoms, which in some cases (e.g., biothreat agents) may be too late. In a BALB/c murine intranasal model of infection for

Copyright © 2013, American Society for Microbiology. All Rights Reserved.

References

  1. Mol Med. 2012 May 09;18:477-85 - PubMed
  2. Immunol Cell Biol. 2007 Feb-Mar;85(2):93-102 - PubMed
  3. Science. 1999 Jul 9;285(5425):248-51 - PubMed
  4. Infect Immun. 1991 Sep;59(9):2922-8 - PubMed
  5. Clin Microbiol Rev. 2002 Oct;15(4):631-46 - PubMed
  6. Infect Immun. 2008 Dec;76(12):5843-52 - PubMed
  7. Int J Antimicrob Agents. 2006 May;27(5):439-43 - PubMed
  8. J Immunol. 2007 Apr 1;178(7):4538-47 - PubMed
  9. Ann N Y Acad Sci. 2007 Jun;1105:1-29 - PubMed
  10. Vaccine. 2009 Nov 5;27 Suppl 4:D48-51 - PubMed
  11. Infect Immun. 2008 Jul;76(7):3001-10 - PubMed
  12. Adv Drug Deliv Rev. 2002 Dec 7;54(12):1615-25 - PubMed
  13. Mol Immunol. 2008 May;45(10):2962-9 - PubMed
  14. FEMS Immunol Med Microbiol. 2011 Aug;62(3):348-61 - PubMed
  15. Microbiology (Reading). 1996 Jun;142 ( Pt 6):1369-1374 - PubMed
  16. JAMA. 1995 Mar 22-29;273(12):934-41 - PubMed
  17. Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):296-301 - PubMed
  18. Microb Pathog. 2011 Jul-Aug;51(1-2):39-47 - PubMed
  19. Infect Immun. 1992 Jan;60(1):84-9 - PubMed
  20. J Leukoc Biol. 2005 Jul;78(1):1-8 - PubMed
  21. Vaccine. 2008 Dec 9;26(52):6874-82 - PubMed
  22. Emerg Infect Dis. 1999 Jul-Aug;5(4):523-7 - PubMed
  23. J Antimicrob Chemother. 1998 Apr;41(4):461-5 - PubMed
  24. Microb Pathog. 1989 Dec;7(6):421-8 - PubMed
  25. Annu Rev Microbiol. 2006;60:167-85 - PubMed
  26. Clin Vaccine Immunol. 2013 Mar;20(3):319-27 - PubMed
  27. Microbiol Mol Biol Rev. 2012 Mar;76(1):16-32 - PubMed
  28. J Leukoc Biol. 2009 Sep;86(3):491-504 - PubMed
  29. J Antimicrob Chemother. 2005 Dec;56(6):1069-73 - PubMed
  30. Ann N Y Acad Sci. 2007 Jun;1105:284-324 - PubMed
  31. J Leukoc Biol. 2009 Sep;86(3):469-70 - PubMed
  32. JAMA. 2001 Jun 6;285(21):2763-73 - PubMed

Publication Types